Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.

吉利德科学公司 （纳斯达克股票代码：GILD）和 Tubulis 今天宣布，双方已达成独家选择权和许可协议，以发现和开发针对实体肿瘤靶点的抗体-药物偶联物(ADC)。

Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.

通过该协议，吉利德将获得 Tubulis 专有的 Tubutecan 和 Alco5 平台的使用权。两家公司将合作选择最佳技术，Tubulis 将领导发现和开发工作，设计一种基于拓扑异构酶 I 抑制剂的 ADC 候选药物，该药物具有卓越的生物物理特性和稳定性，可解决目前的治疗挑战，例如耐久性和脱靶毒性。

“As we expand our oncology portfolio to address the greatest gaps in care, accessing novel technologies is critical to advancing our pipeline,” said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences. “With Gilead’s ongoing focus on innovating with next-generation therapies and combinations, we are excited to partner with Tubulis to explore a range of solutions that may help increase the therapeutic value of the ADC modality.”

吉利德科学研究执行副总裁 Flavius Martin 医学博士表示：“随着我们扩大肿瘤学产品组合以解决治疗方面的最大差距，获得新技术对于推进我们的产品线至关重要。吉利德持续专注于创新下一代疗法和组合，我们很高兴与 Tubulis 合作探索一系列可能有助于提高 ADC 治疗方式治疗价值的解决方案。”

“Gilead has established a long track record of developing drugs that provide a significant step-up in therapeutic value, making them a great collaborator for leveraging our technology platforms, in line with our vision of fundamentally changing the ADC landscape,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “Tubulis remains primarily focused on driving value through our own clinical development programs while selectively building partnerships with leaders in the industry.”

Tubulis 首席执行官兼联合创始人 Dominik Schumacher 博士表示：“吉利德在开发能够显著提高治疗价值的药物方面有着悠久的历史，这使他们成为利用我们技术平台的优秀合作伙伴，这符合我们从根本上改变 ADC 格局的愿景。Tubulis 仍然主要专注于通过我们自己的临床开发项目来推动价值，同时有选择地与行业领导者建立合作伙伴关系。”

Terms of the Agreement

协议条款

Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million. In addition, Tubulis will be eligible for development and commercialization milestone payments totaling up to $415 million, plus mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. Tubulis will lead early-stage research and development activities for the ADC program. If Gilead exercises its option to exclusively license the program, Gilead will be responsible for further development and commercialization activities for all products resulting from the collaboration.

根据协议条款，Tubulis 将获得 2000 万美元的预付款，如果吉利德行使选择权，还将获得 3000 万美元的单独选择权行使费。此外，Tubulis 将有资格获得总计高达 4.15 亿美元的开发和商业化里程碑付款，以及合作产生的上市产品销售额的中个位数至低两位数分级特许权使用费。Tubulis 将领导 ADC 项目的早期研发活动。如果吉利德行使独家授权该项目的选择权，吉利德将负责合作产生的所有产品的进一步开发和商业化活动。

Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Tubulis is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.01.

吉利德不将收购的知识产权和开发费用排除在其非公认会计准则财务指标之外。与 Tubulis 的此次交易预计将使吉利德的 GAAP 和非 GAAP 2024 年每股收益减少约 0.01 美元。